Table 3.
Median survival in selected subgroups
| Patients | PFS (months) | P | OS (months) | P |
|---|---|---|---|---|
| All (n = 53) | 16 (10.6–21.4) | – | 28 (23.2–32.7) | – |
| Early response (n = 15) | 28 (16–41) | 0.024 | 28 (18.7–37.3) | 0.55 |
| No early response (n = 38) | 9 (6–12) | 28 (22.6–33.3) | ||
| Early tumor shrinkage (n = 27) | 25 (12–38) | 0.006 | Median not reached | 0.006 |
| No early tumor shrinkage (n = 26) | 9 (4–14) | 22 (20–24) | ||
| Mutated K-ras (n = 20) | 13.7 (2.6–24.8) | 0.88 | 24.7 (17.0–32.4) | 0.82 |
| Wild-type K-ras (n = 20) | 15.8 (6.8–24.8) | 27.7 (23–32.6) | ||
| Surgical resection (n = 13) | Median not reached | 0.001 | Median not reached | 0.002 |
| No surgical resection (n = 40) | 9 (5–19) | 23 (18–28) |
Figures in parentheses are 95% CI. PFS, progression-free survival; OS, overall survival.